Neuronetics Opens Largest Interventional Psychiatry Center in Rockville — Neuronetics, Inc.

Event summary

Neuronetics opened a 7,000-square-foot National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland on July 28, 2026.
The facility is the largest Greenbrook center to date and serves as a blueprint for advanced patient-centered mental health care delivery.
The center offers NeuroStar TMS therapy and SPRAVATO nasal spray treatments, with plans to evaluate emerging psychedelic-class therapies.
Geoffrey Grammer, M.D., Chief Medical Officer of Neuronetics, provides clinical leadership and direct patient care at the facility.

The big picture

Neuronetics' investment in this flagship facility underscores the growing demand for non-pharmacological and advanced interventional treatments for mental health conditions. The center positions Neuronetics at the forefront of clinical innovation, addressing treatment-resistant depression and other psychiatric conditions through a scalable, patient-centered approach. This strategic move aligns with broader industry trends toward personalized and technology-driven mental healthcare solutions.

What we're watching

Clinical Innovation: The pace at which the Rockville center will accelerate the evaluation and integration of emerging psychedelic-class therapies into Greenbrook's treatment model.
Market Expansion: Whether Neuronetics can successfully scale this Center of Excellence model across its network to improve access to advanced interventional treatments.
Regulatory Dynamics: How the FDA's approval process for new psychiatric treatments will impact Greenbrook's ability to incorporate innovative therapies into its care model.